Nonlinear dynamics of Shear Alfv\'en fluctuations in Divertor Tokamak Test facility plasmas

Following the analysis on linear spectra of shear Alfv\'en fluctuations excited by energetic particles (EPs) in the Divertor Tokamak Test (DTT) facility plasmas [T. Wang et al., Phys. Plasmas 25, 062509 (2018)], in this work, nonlinear dynamics of the corresponding mode saturation and the fluctuation induced EP transport is studied by hybrid magnetohydrodynamic-gyrokinetic simulations. For the reversed shear Alfv\'en eigenmode driven by magnetically trapped EP precession resonance in the central core region of DTT plasmas, the saturation is mainly due to radial decoupling of resonant trapped EPs. Consistent with the wave-EP resonance structure, EP transport occurs in a similar scale to the mode width. On the other hand, passing EP transport is analyzed in detail for toroidal Alfv\'en eigenmode in the outer core region, with mode drive from both passing and trapped EPs. It is shown that passing EPs experience only weak redistributions in the weakly unstable case; and the transport extends to meso-scale diffusion in the strongly unstable case, due to orbit stochasticity induced by resonance overlap. Here, weakly/strongly unstable regime is determined by Chirikov condition for resonance overlap. This work then further illuminates rich and diverse nonlinear EP dynamics related to burning plasma studies, and the capability of DTT to address these key physics.Comment: 32 pages, 20 figure

Workload Decomposition Strategies for Shared Memory Parallel Systems with OpenMP

A crucial issue in parallel programming (both for distributed and shared memory architectures) is work decomposition. Work decomposition task can be accomplished without large programming effort with use of high-level parallel programming languages, such as OpenMP. Anyway particular care must still be payed on achieving performance goals. In this paper we introduce and compare two decomposition strategies, in the framework of shared memory systems, as applied to a case study particle in cell application. A number of different implementations of them, based on the OpenMP language, are discussed with regard to time efficiency, memory occupancy, and program restructuring effort

Nonlinear dynamics of phase space zonal structures and energetic particle physics in fusion plasmas

A general theoretical framework for investigating nonlinear dynamics of phase space zonal structures is presented in this work. It is then, more specifically, applied to the limit where the nonlinear evolution time scale is smaller or comparable to the wave-particle trapping period. In this limit, both theoretical and numerical simulation studies show that non-adiabatic frequency chirping and phase locking could lead to secular resonant particle transport on meso- or macro-scales. The interplay between mode structures and resonant particles then provides the crucial ingredient to properly understand and analyze the nonlinear dynamics of Alfv\'en wave instabilities excited by non-perturbative energetic particles in burning fusion plasmas. Analogies with autoresonance in nonlinear dynamics and with superradiance in free electron lasers are also briefly discussed

Workload Decomposition Strategies for Shared Memory Parallel Systems with OpenMP

A crucial issue in parallel programming (both for distributed and shared memory architectures) is work decomposition. Work decomposition task can be accomplished without large programming effort with use of high-level parallel programming languages, such as OpenMP. Anyway particular care must still be payed on achieving performance goals. In this paper we introduce and compare two decomposition strategies, in the framework of shared memory systems, as applied to a case study particle in cell application. A number of different implementations of them, based on the OpenMP language, are discussed with regard to time efficiency, memory occupancy, and program restructuring effort

Corrigendum: Current drive at plasma densities required for thermonuclear reactors

Nature Communications 1: Article number: 55 (2010); Published: 10 August 2010; Updated:19 September 2013. In Fig. 3 of this Article, the colours of the blue and green curves were accidentally interchanged while the manuscript was being revised. In addition, the x axis labels on Fig. 4 should have read 'Frequency (MHz)'

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

EUROfusion Integrated Modelling (EU-IM) capabilities and selected physics applications

International audienceRecent developments and achievements of the EUROfusion Code Development for Integrated Modelling project (WPCD), which aim is to provide a validated integrated modelling suite for the simulation and prediction of complete plasma discharges in any tokamak, are presented. WPCD develops generic complex integrated simulations, workflows, for physics applications, using the standardized European Integrated Modelling (EU-IM) framework. Selected physics applications of EU-IM workflows are illustrated in this paper